Beijing Hebikon Technology Development

Hebikon is a clinical-stage biopharmaceutical company based in Beijing, China, specializing in the discovery and development of innovative therapies for metabolic diseases and oncology. The company's lead program, HBK-001, is a multi-target agonist (GLP-1/GIP/GCG) designed to treat type 2 diabetes and obesity with improved efficacy and safety profiles. Hebikon leverages its expertise in peptide engineering and metabolic signaling to build a robust pipeline of next-generation metabolic regulators. The company is backed by prominent venture capital firms and focuses on addressing significant unmet medical needs in the global healthcare market. Beyond metabolic health, Hebikon is exploring therapeutic candidates for oncology and other chronic conditions.